Generic Fosamax Plaintiffs Say Bartlett Doesn't Apply, Warning Labels Outdated

Generic Fosamax Plaintiffs Say Bartlett Doesn't Apply, Warning Labels Outdated

NEW YORK - The U.S. Supreme Court's June ruling on the preemption of generic drug design defect claims does not apply to "pure design defect" claims involving generic versions of the osteoporosis drug Fosamax, plaintiffs told a New York multidistrict litigation court on July 19 (In Re: Fosamax Products Liability Litigation, MDL Docket No. 1789, No. 1:06-md-1789, S.D. N.Y.).

Find full version on lexis Advance®
Access this news story on lexis.com®